BRAF and neoplasm: We specifically included genetic lesions and tumor specimens that are challenging to detect or interpret by NGS such as FLT3-ITD, KIAA1549-BRAF fusion, variants from high-GC exons21, complex structural rearrangements, and samples with low tumor purity, intra-tumor heterogeneity, and/or tumor-in-normal contamination (Supplementary Data 2, 3).